company background image
BICT.F logo

Biocure Technology OTCPK:BICT.F Stock Report

Last Price

US$0.07

Market Cap

US$897.9k

7D

0%

1Y

833.3%

Updated

27 Nov, 2023

Data

Company Financials

Biocure Technology Inc.

OTCPK:BICT.F Stock Report

Market Cap: US$897.9k

BICT.F Stock Overview

Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab.

BICT.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance4/6
Financial Health3/6
Dividends0/6

Biocure Technology Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biocure Technology
Historical stock prices
Current Share PriceCA$0.07
52 Week HighCA$0.07
52 Week LowCA$0.0035
Beta2.51
1 Month Change0%
3 Month Changen/a
1 Year Change833.33%
3 Year Change-20.72%
5 Year Change-82.93%
Change since IPO-82.93%

Recent News & Updates

Recent updates

Shareholder Returns

BICT.FUS BiotechsUS Market
7D0%-1.7%1.0%
1Y833.3%12.6%31.2%

Return vs Industry: BICT.F exceeded the US Biotechs industry which returned -3.5% over the past year.

Return vs Market: BICT.F exceeded the US Market which returned 15.2% over the past year.

Price Volatility

Is BICT.F's price volatile compared to industry and market?
BICT.F volatility
BICT.F Average Weekly Movementn/a
Biotechs Industry Average Movement11.8%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: BICT.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine BICT.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005n/aSimon Chenghttps://www.biocuretech.com

Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; and hair growth products.

Biocure Technology Inc. Fundamentals Summary

How do Biocure Technology's earnings and revenue compare to its market cap?
BICT.F fundamental statistics
Market capUS$897.85k
Earnings (TTM)US$1.82m
Revenue (TTM)n/a

0.5x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BICT.F income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other Expenses-CA$2.48m
EarningsCA$2.48m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.03
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio3.1%

How did BICT.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.